Loading
A multicentre study of a combined DNA, RNA and microRNA test on uncertain thyroid nodules.
The multiplatform test had 95 per cent sensitivity, 90 per cent specificity, a 97 per cent negative predictive value and a 75 per cent positive predictive value.
Adding microRNA to DNA and RNA fusion testing gave high negative predictive value.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Biomarker, Thyroid cancer.
Shares ThyGeNEXT and ThyraMIR v2, Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Biomarker, Thyroid cancer.
Shares ThyGeNEXT and ThyraMIR v2, Thyroid nodule FNA, Bethesda cytology & molecular classifiers.
Shares ThyGeNEXT and ThyraMIR v2, Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/